TPST (Tempest Therapeutics Inc.) stock: $0.97, $16.0M market cap, $0.8M cash, $15.2M EV, $28.3M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
TPST-4003
Preclinical · Active Modality: In vivo CAR-T (CD7-targeted mRNA lipid nanoparticle delivery platform, CD7-tLNP)
Target CD19/BCMA
Partnerships Senlang: collaboration to develop TPST-4003 beginning with the China IIT; Senlang holds an exclusive option to negotiate a definitive license agreement for TPST-4003 in China
Indications- Myasthenia gravis (planned investigator-initiated trial) (Preclinical)
- Multiple sclerosis (planned investigator-initiated trial) (Preclinical)
Status note Lead program. Combines the CD7-tLNP mRNA delivery platform with the same dual-targeting CD19/BCMA CAR architecture as TPST-2003. China IIT expected to enroll approximately 10 patients with nervous system autoimmune diseases.
TPST-2003
Phase 1 · Active Modality: Autologous CAR-T
Target CD19/BCMA
Partnerships Erigen LLC / Factor Bioscience Inc. (asset purchase, Nov 2025): acquired all rights to TPST-2003 and three additional CAR-T programs. Cincinnati Children's Applied Gene and Cell Therapy Center (AGCTC): manufacturing partner
Indications- Relapsed/refractory multiple myeloma (REDEEM-1, Phase 1) (Phase 1)
- POEMS syndrome (POEMS-1, Phase 1) (Phase 1)
Status note Autologous dual-targeting CAR-T therapy. Two ongoing Phase 1 trials (REDEEM-1 in rrMM, POEMS-1 in POEMS syndrome). First potentially registrational study in rrMM planned to initiate later in 2026.
TPST-2206
Preclinical · Active Modality: Autologous CAR-T
Target CD70
Partnerships Erigen LLC / Factor Bioscience Inc. (acquired Nov 2025)
Indications- not disclosed (Stage not disclosed)
Status note Autologous dual-targeting CAR-T; requires substantial U.S.-specific development activities before generating economic benefit.
TPST-3003
Preclinical · Active Modality: Allogeneic CAR-T (TRAC locus gene edit inactivating the T cell receptor)
Target BCMA/CD19
Partnerships Erigen LLC / Factor Bioscience Inc. (acquired Nov 2025)
Indications- not disclosed (Stage not disclosed)
Status note Discovery-stage allogeneic BCMA/CD19 dual-targeting CAR-T.
TPST-3206
Preclinical · Active Modality: Allogeneic CAR-T (TRAC locus gene edit inactivating the T cell receptor)
Target CD70
Partnerships Erigen LLC / Factor Bioscience Inc. (acquired Nov 2025)
Indications- not disclosed (Stage not disclosed)
Status note Discovery-stage allogeneic CD70/CD70 dual-targeting CAR-T.
Amezalpat
Stage not disclosed · Active
Target PPARα
Indications- not disclosed (Stage not disclosed)
Status note Company's most advanced product candidate; paused while the company completes its ongoing strategic review.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.